Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Obesity Setbacks For Amylin And Takeda

This article was originally published in The Pink Sheet Daily

Executive Summary

A Phase II trial for their Symlin-based combination therapy was halted after safety issues cropped up with patients from a previous study.

You may also be interested in...



Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty

Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."

Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty

Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."

EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa

The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel